Tags

Type your tag names separated by a space and hit enter

Response to 2009 pandemic and seasonal influenza vaccines co-administered to HIV-infected and HIV-uninfected former drug users living in a rehabilitation community in Italy.
Vaccine. 2011 Nov 15; 29(49):9209-13.V

Abstract

BACKGROUND

2009 A(H1N1) pandemic influenza vaccination was recommended as a priority to essential workers and high-risk individuals, including HIV-infected patients and people living in communities.

METHODS

HIV-infected and HIV-uninfected former drug-users (18-60 years old) living in a rehabilitation community (San Patrignano, Italy) received one dose of a MF59-adjuvanted 2009 pandemic influenza vaccine and one dose of a 2009-2010 seasonal trivalent inactivated influenza vaccine (containing A/Brisbane/59/2007(H1N1), A/Brisbane/10/2007(H3N2), B/Brisbane/60/2008) simultaneously. Antibodies against each vaccine antigen were determined at the time of vaccination and one and six months post-vaccination by hemagglutination-inhibition test.

RESULTS

49 HIV-infected and 60 HIV-uninfected subjects completed the study. Most (98%) HIV-infected participants were on antiretroviral treatment, the median CD4+ cell count was 350 (IQR 300)cells/μl and viremia was suppressed in 91.8% of cases. One month post-vaccination, no significant changes in immune-virological parameters were observed. One month post-vaccination, the immune responses to both pandemic and seasonal vaccine met the EMA-CPMP criteria for immunogenicity of influenza vaccines in both HIV-infected and HIV-uninfected subjects. No difference in vaccine responses was observed between the two groups. Six months after vaccination, the percentages of vaccinees with antibody titres ≥1:40 and antibody geometric mean titres significantly decreased in both groups. However, they were significantly lower in HIV-infected than in HIV-uninfected vaccinees. In subjects who had been primed to seasonal influenza the year before (through either vaccination or natural infection), levels of antibodies against 2009 A(H1N1) were higher than those measured in unprimed subjects, both one month and six months post-vaccination.

CONCLUSIONS

The co-administration of a single dose of 2009 pandemic MF59-adjuvanted influenza vaccine with a seasonal vaccine provided a protective immune response in both HIV-infected and HIV-uninfected individuals. Subjects who had been primed to seasonal influenza in the year preceding the pandemic had a more vigorous and long-lasting antibody response to 2009 pandemic vaccine.

Authors+Show Affiliations

Università degli Studi di Milano, Dipartimento di Sanità Pubblica-Microbiologia-Virologia, Milan, Italy. elena.pariani@unimi.itNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

21974995

Citation

Pariani, Elena, et al. "Response to 2009 Pandemic and Seasonal Influenza Vaccines Co-administered to HIV-infected and HIV-uninfected Former Drug Users Living in a Rehabilitation Community in Italy." Vaccine, vol. 29, no. 49, 2011, pp. 9209-13.
Pariani E, Boschini A, Amendola A, et al. Response to 2009 pandemic and seasonal influenza vaccines co-administered to HIV-infected and HIV-uninfected former drug users living in a rehabilitation community in Italy. Vaccine. 2011;29(49):9209-13.
Pariani, E., Boschini, A., Amendola, A., Poletti, R., Anselmi, G., Begnini, M., Ranghiero, A., Cecconi, G., & Zanetti, A. R. (2011). Response to 2009 pandemic and seasonal influenza vaccines co-administered to HIV-infected and HIV-uninfected former drug users living in a rehabilitation community in Italy. Vaccine, 29(49), 9209-13. https://doi.org/10.1016/j.vaccine.2011.09.103
Pariani E, et al. Response to 2009 Pandemic and Seasonal Influenza Vaccines Co-administered to HIV-infected and HIV-uninfected Former Drug Users Living in a Rehabilitation Community in Italy. Vaccine. 2011 Nov 15;29(49):9209-13. PubMed PMID: 21974995.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Response to 2009 pandemic and seasonal influenza vaccines co-administered to HIV-infected and HIV-uninfected former drug users living in a rehabilitation community in Italy. AU - Pariani,Elena, AU - Boschini,Antonio, AU - Amendola,Antonella, AU - Poletti,Raffaella, AU - Anselmi,Giovanni, AU - Begnini,Marco, AU - Ranghiero,Alberto, AU - Cecconi,Gianluca, AU - Zanetti,Alessandro R, Y1 - 2011/10/03/ PY - 2011/07/20/received PY - 2011/09/20/revised PY - 2011/09/26/accepted PY - 2011/10/7/entrez PY - 2011/10/7/pubmed PY - 2012/3/1/medline SP - 9209 EP - 13 JF - Vaccine JO - Vaccine VL - 29 IS - 49 N2 - BACKGROUND: 2009 A(H1N1) pandemic influenza vaccination was recommended as a priority to essential workers and high-risk individuals, including HIV-infected patients and people living in communities. METHODS: HIV-infected and HIV-uninfected former drug-users (18-60 years old) living in a rehabilitation community (San Patrignano, Italy) received one dose of a MF59-adjuvanted 2009 pandemic influenza vaccine and one dose of a 2009-2010 seasonal trivalent inactivated influenza vaccine (containing A/Brisbane/59/2007(H1N1), A/Brisbane/10/2007(H3N2), B/Brisbane/60/2008) simultaneously. Antibodies against each vaccine antigen were determined at the time of vaccination and one and six months post-vaccination by hemagglutination-inhibition test. RESULTS: 49 HIV-infected and 60 HIV-uninfected subjects completed the study. Most (98%) HIV-infected participants were on antiretroviral treatment, the median CD4+ cell count was 350 (IQR 300)cells/μl and viremia was suppressed in 91.8% of cases. One month post-vaccination, no significant changes in immune-virological parameters were observed. One month post-vaccination, the immune responses to both pandemic and seasonal vaccine met the EMA-CPMP criteria for immunogenicity of influenza vaccines in both HIV-infected and HIV-uninfected subjects. No difference in vaccine responses was observed between the two groups. Six months after vaccination, the percentages of vaccinees with antibody titres ≥1:40 and antibody geometric mean titres significantly decreased in both groups. However, they were significantly lower in HIV-infected than in HIV-uninfected vaccinees. In subjects who had been primed to seasonal influenza the year before (through either vaccination or natural infection), levels of antibodies against 2009 A(H1N1) were higher than those measured in unprimed subjects, both one month and six months post-vaccination. CONCLUSIONS: The co-administration of a single dose of 2009 pandemic MF59-adjuvanted influenza vaccine with a seasonal vaccine provided a protective immune response in both HIV-infected and HIV-uninfected individuals. Subjects who had been primed to seasonal influenza in the year preceding the pandemic had a more vigorous and long-lasting antibody response to 2009 pandemic vaccine. SN - 1873-2518 UR - https://www.unboundmedicine.com/medline/citation/21974995/Response_to_2009_pandemic_and_seasonal_influenza_vaccines_co_administered_to_HIV_infected_and_HIV_uninfected_former_drug_users_living_in_a_rehabilitation_community_in_Italy_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0264-410X(11)01545-3 DB - PRIME DP - Unbound Medicine ER -